Source: Eur Respir Monogr 2020; 88: 229-237
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Maria Gabriella Matera, Reynold A. Panettieri. ß₂-adrenoceptor modulation in COPD and its potential impact on cardiovascular comorbidities. Eur Respir Monogr 2020; 88: 229-237

Member's Comments

No comment yet.

Related content which might interest you: The impact of aging on COPD, cardiovascular comorbidities and systemic inflammation Source: International Congress 2019 – Cardiovascular comorbidities in COPD Year: 2019 Impact of cardiovascular comorbidities on COPD exacerbations Source: Annual Congress 2007 - COPD and comorbidity Year: 2007 The association between COPD and cardiovascular disorders Source: International Congress 2017 – COPD and comorbid cardiovascular diseases Year: 2017 The impact of cardiovascular drugs in COPD Source: Annual Congress 2011 - Knowing COPD by heart: a relationship beyond comorbidity Year: 2011 The association of respiratory health and cardiovascular risk with structural brain disease in patients with COPD Source: International Congress 2018 – COPD and extrapulmonary comorbidities Year: 2018 The impact of airway infection on cardiovascular risk during COPD exacerbations Source: Annual Congress 2012 - Acute exacerbation in COPD Year: 2012 Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities Source: Virtual Congress 2021 – Comorbidities in airway obstructive diseases Year: 2021 Does overweight/obesity influence cardiac autonomic modulation and functional performance in COPD exacerbation? Source: International Congress 2018 – Acutely hospitalised patients: physiotherapy interventions and assessment methods Year: 2018 Frequency of occurrence of risk factors of cardiovascular diseases and assessment of the total cardiovascular risk in patients with chronic obstructive pulmonary disease (COPD). Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 Acute exacerbation in COPD and relationship between cardiovascular risk and functional profile Source: International Congress 2018 – Telehealth, home rehabilitation and specific adaptations to exercise interventions in different settings Year: 2018 The impact of comorbidities related to BMI in COPD patients Source: Annual Congress 2011 - COPD mechanisms Year: 2011 Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits Source: Eur Respir Monogr 2020; 88: 66-81 Year: 2020 The effect of comorbidities on long-term survival in COPD Source: International Congress 2018 – COPD and extrapulmonary comorbidities Year: 2018 Is there a strong relationship between COPD and cardiovascular diseases? Source: Annual Congress 2013 –The latest insights in respiratory muscles, neuromuscular disease and comorbidities Year: 2013 Coexisting cardiovascular diseases increase the risk of exacerbations in patients with COPD Source: Annual Congress 2011 - Respiratory epidemiology: comorbidity Year: 2011 Pharmacological treatment of self-reported cardiovascular comorbidity in COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 453s Year: 2007 Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia Source: Eur Respir J 2014; 43: 36-42 Year: 2004 The impact of comorbidities on the short-term serious health outcomes in hospitalized COPD patients due to exacerbation Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Do cardiovascular drugs reduce mortality in patients with COPD in daily practice? A study in primary care Source: Annual Congress 2007 - Management of COPD: pushing forward the boundaries in primary care Year: 2007 Effects of cardiovascular agents on respiratory function in COPD patients with concomitant coronary heart disease Source: Eur Respir J 2002; 20: Suppl. 38, 247s Year: 2002